JPRN-UMIN000000676尚未招募未知
Comparative study of glimepiride and nateglinide on glycemic control in patients with type 2 diabetes mellitus treated with voglibose - Comparative study of glimepiride and nateglinide in type 2 diabetes mellitus
agoya University Graduate School of Medicine0 个研究点目标入组 60 人开始时间: 2009年1月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients without type 2 diabetes 2) Patients with alcohol abuse or excessive intake of alcoholic beverages 3) Patients with severe diabetic complications* *nephropathy>=stage 3A *retinopathy>=preproliferative stage in Davis classifications 4) Patients with liver dysfunction (AST and ALT>=80 IU/L) or renal dysfunction (serum creatinie>=1.5mg/dl) 5) Patients with an allergy to any drug 6) Pregnant women and women at child bearing age and not taking adequate contraceptions 7) Patients decided to be irrelevant by the investigators
研究者
相似试验
已完成
不适用
A group comparison between gliclazide and glimepiride among type 2 diabetic patients using sitagliptin.JPRN-UMIN000003953Hokuriku Incretin-based Therapy Study Group (HINT Study Group)50
已完成
2 期
A comparative study of Sitagliptin- Glimepiride combinational therapy and Glimepiride monotherapy on the patients with diabetes mellitus after pancreatic biliary diseases including malignant disorders related subtotal pancreatectomyDiabetes mellitus after pancreatic biliary diseases including malignant disorders related subtotal pancreatectomyJPRN-UMIN000004645Hiroshima University Hospital Department of Endocrinology and Diabetes mellitus60
已完成
不适用
Comparison of sitagliptin and glimepiride in patients with type 2 diabetes mellitusType 2 diabetes mellitusJPRN-UMIN000017566Jichi Medical University200
尚未招募
4 期
Sitagliptin compared to glimepiride on vascular risk factors among patients with type 2 diabetes mellitusType 2 Diabetes MellitusSLCTR/2015/022niversity Grants Commission, Sri Lanka
尚未招募
不适用
Study of antidiabetic drugs on markers of inflammation in type 2 diabetes mellitus patients.CTRI/2018/03/012603MALEHA BUT